{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"86.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Body temperature was derived from vital signs evaluation. No conversion of body temperature was performed, no matter how it was measured.","groups":[{"description":"Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\\>37.5 kg) received two sc injections.","id":"OG000","title":"Canakinumab"},{"description":"Patients received a single dose matching placebo of canakinumab on day 1.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients who received at least one dose of study drug. Only observed cases were used in the analysis.","reportingStatus":"POSTED","timeFrame":"Day 3","title":"Percentage of Patients Who Had Body Temperature ≤ 38°C","type":"SECONDARY","unitOfMeasure":"Percent of participants"}